Abstract：
OBJECTIVE: There is a significant association between cardiovascular diseases (CVD) and prostate cancer (PCa), leading to high mortality. This study evaluates the trends in mortality associated with CVDs and PCa among older (≥ 65 years) men in the United States (US).
METHODS: This analysis utilized the Centers for Disease Control and Prevention\'s Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER). The analysis of Multiple Cause of Death Files was carried out from 1999 to 2019 to identify fatalities with CVD and PCa listed as either contributory or underlying causes of death. Crude and age-adjusted mortality rates (AAMRs) per 100,000 populations for variables such as year, race and ethnicity, and geographic regions were determined. To assess annual percent change (APC), a Joinpoint regression program was employed.
RESULTS: Overall AAMR was 54.3 in 1999 and 34.6 in 2019. After a decline in AAMR from 1999 to 2015, an alarming rise in mortality was observed until 2019. Mortality rates were highest among Non-Hispanic (NH) Black and African American men (74.9). Geographically, the highest mortalities were witnessed in the West (46.4) and non-metropolitan areas (44.6). States with AAMRs ranking in the 90th percentile were Nebraska, California, North Dakota, the District of Columbia, and Mississippi.
CONCLUSIONS: After decreasing death rates associated with CVD and PCa from 1999 to 2015, a reversal in the trend was observed from 2015 to 2019. Addressing this increase in death rates, especially among the vulnerable population, requires focused attention and targeted strategies to implement necessary safeguards in the upcoming years.
METHODS: This analysis utilized the Centers for Disease Control and Prevention\'s Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER). The analysis of Multiple Cause of Death Files was carried out from 1999 to 2019 to identify fatalities with CVD and PCa listed as either contributory or underlying causes of death. Crude and age-adjusted mortality rates (AAMRs) per 100,000 populations for variables such as year, race and ethnicity, and geographic regions were determined. To assess annual percent change (APC), a Joinpoint regression program was employed.
RESULTS: Overall AAMR was 54.3 in 1999 and 34.6 in 2019. After a decline in AAMR from 1999 to 2015, an alarming rise in mortality was observed until 2019. Mortality rates were highest among Non-Hispanic (NH) Black and African American men (74.9). Geographically, the highest mortalities were witnessed in the West (46.4) and non-metropolitan areas (44.6). States with AAMRs ranking in the 90th percentile were Nebraska, California, North Dakota, the District of Columbia, and Mississippi.
CONCLUSIONS: After decreasing death rates associated with CVD and PCa from 1999 to 2015, a reversal in the trend was observed from 2015 to 2019. Addressing this increase in death rates, especially among the vulnerable population, requires focused attention and targeted strategies to implement necessary safeguards in the upcoming years.
摘要：
目的：心血管疾病（CVD）与前列腺癌（PCa）之间存在显着关联，导致高死亡率。这项研究评估了美国（US）老年（≥65岁）男性中与CVD和PCa相关的死亡率趋势。
方法：本分析利用了疾病控制和预防中心的广泛的流行病学研究在线数据（CDCWONDER）。从1999年到2019年进行了多种死亡原因档案的分析，以确定CVD和PCa被列为死亡原因或潜在死亡原因。每100,000人口的粗死亡率和年龄调整死亡率(AAMR)，例如年份，种族和民族,并确定了地理区域。为了评估年度百分比变化(APC)，采用关节点回归程序。
结果：1999年的总体AAMR为54.3，2019年为34.0。在1999年至2015年AAMR下降之后，直到2019年，死亡率都出现了惊人的上升。非西班牙裔（NH）黑人和非裔美国男性的死亡率最高（74.6）。地理上,死亡率最高的地区是西部（46.3）和非大都市地区（44.6）。AAMR排名在第90百分位的州是北达科他州，加州,内布拉斯加州,哥伦比亚特区,还有密西西比州.
结论：在1999年至2015年与CVD和PCa相关的死亡率下降之后，从2015年至2019年观察到趋势逆转。解决死亡率上升的问题，特别是在弱势群体中，需要集中关注和有针对性的战略，以在未来几年实施必要的保障措施。
方法：本分析利用了疾病控制和预防中心的广泛的流行病学研究在线数据（CDCWONDER）。从1999年到2019年进行了多种死亡原因档案的分析，以确定CVD和PCa被列为死亡原因或潜在死亡原因。每100,000人口的粗死亡率和年龄调整死亡率(AAMR)，例如年份，种族和民族,并确定了地理区域。为了评估年度百分比变化(APC)，采用关节点回归程序。
结果：1999年的总体AAMR为54.3，2019年为34.0。在1999年至2015年AAMR下降之后，直到2019年，死亡率都出现了惊人的上升。非西班牙裔（NH）黑人和非裔美国男性的死亡率最高（74.6）。地理上,死亡率最高的地区是西部（46.3）和非大都市地区（44.6）。AAMR排名在第90百分位的州是北达科他州，加州,内布拉斯加州,哥伦比亚特区,还有密西西比州.
结论：在1999年至2015年与CVD和PCa相关的死亡率下降之后，从2015年至2019年观察到趋势逆转。解决死亡率上升的问题，特别是在弱势群体中，需要集中关注和有针对性的战略，以在未来几年实施必要的保障措施。
